Investment analysts at Credit Suisse Group assumed coverage on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) in a note issued to investors on Wednesday. The firm set an “outperform” rating and a $67.00 price target on the biopharmaceutical company’s stock. Credit Suisse Group’s price objective indicates a potential upside of 46.26% from the stock’s previous close.

A number of other equities research analysts have also weighed in on RARE. BidaskClub raised shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Saturday, January 6th. Zacks Investment Research lowered shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. Robert W. Baird reissued a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Tuesday, September 19th. Morgan Stanley reissued an “equal weight” rating and set a $71.00 target price (up from $69.00) on shares of Ultragenyx Pharmaceutical in a report on Friday, October 6th. Finally, Raymond James Financial reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a research note on Friday, December 15th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $72.06.

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) traded down $1.99 during trading hours on Wednesday, hitting $45.81. 362,000 shares of the stock traded hands, compared to its average volume of 404,910. The firm has a market cap of $2,030.00, a PE ratio of -6.57 and a beta of 1.83. Ultragenyx Pharmaceutical has a one year low of $43.14 and a one year high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($1.87). The business had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.02 million. During the same period in the previous year, the firm earned ($1.64) earnings per share. The company’s revenue was up 81.8% compared to the same quarter last year. equities research analysts anticipate that Ultragenyx Pharmaceutical will post -7.31 earnings per share for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in RARE. Capital International Investors lifted its position in shares of Ultragenyx Pharmaceutical by 21.9% during the 3rd quarter. Capital International Investors now owns 2,895,481 shares of the biopharmaceutical company’s stock valued at $154,213,000 after acquiring an additional 520,496 shares during the period. BlackRock Inc. lifted its position in shares of Ultragenyx Pharmaceutical by 10.4% during the 2nd quarter. BlackRock Inc. now owns 3,497,591 shares of the biopharmaceutical company’s stock valued at $217,237,000 after acquiring an additional 330,911 shares during the period. State Street Corp lifted its position in shares of Ultragenyx Pharmaceutical by 21.4% during the 2nd quarter. State Street Corp now owns 1,536,285 shares of the biopharmaceutical company’s stock valued at $95,417,000 after acquiring an additional 270,729 shares during the period. Royal Bank of Canada lifted its position in shares of Ultragenyx Pharmaceutical by 933.2% during the 2nd quarter. Royal Bank of Canada now owns 224,261 shares of the biopharmaceutical company’s stock valued at $13,929,000 after acquiring an additional 202,556 shares during the period. Finally, Pictet Asset Management Ltd. lifted its position in shares of Ultragenyx Pharmaceutical by 27.4% during the 3rd quarter. Pictet Asset Management Ltd. now owns 750,407 shares of the biopharmaceutical company’s stock valued at $39,967,000 after acquiring an additional 161,196 shares during the period. Institutional investors own 94.10% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Ultragenyx Pharmaceutical (RARE) Research Coverage Started at Credit Suisse Group” was first published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2018/01/17/ultragenyx-pharmaceutical-rare-research-coverage-started-at-credit-suisse-group.html.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.